Revenue (TTM) Chart

View Revenue (TTM) for RHHBY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (TTM) Chart
Start Trial

Historical Revenue (TTM) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 76.81B
December 31, 2025 74.12B
June 30, 2025 71.04B
December 31, 2024 68.70B
June 30, 2024 66.23B
December 31, 2023 65.33B
June 30, 2023 64.75B
December 31, 2022 66.29B
June 30, 2022 69.07B
December 31, 2021 68.69B
June 30, 2021 65.66B
December 31, 2020 62.16B
June 30, 2020 61.69B
December 31, 2019 61.85B
June 30, 2019 59.50B
December 31, 2018 58.09B
June 30, 2018 56.71B
December 31, 2017 54.16B
June 30, 2017 52.37B
December 31, 2016 51.34B
June 30, 2016 50.60B
December 31, 2015 50.01B
June 30, 2015 50.98B
December 31, 2014 51.94B
June 30, 2014 51.45B
Date Value
December 31, 2013 50.44B
June 30, 2013 49.22B
December 31, 2012 48.63B
June 30, 2012 48.29B
December 31, 2011 47.97B
June 30, 2011 46.72B
December 31, 2010 45.52B
June 30, 2010 46.77B
December 31, 2009 45.27B
June 30, 2009 42.43B
December 31, 2008 42.14B
June 30, 2008 40.82B
December 31, 2007 38.46B
June 30, 2007 36.54B
December 31, 2006 33.58B
June 30, 2006 30.30B
December 31, 2005 28.43B
June 30, 2005 26.05B
December 31, 2004 23.76B
June 30, 2004 23.35B
December 31, 2003 23.22B
June 30, 2003 21.49B
December 31, 2002 19.15B
June 30, 2002 17.80B
December 31, 2001 17.27B

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

View Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (TTM) Benchmarks

View Revenue (TTM) Benchmarks
Start Trial
Novartis AG 54.79B
AstraZeneca PLC 60.48B
Eli Lilly & Co. 79.67B
Merck & Co., Inc. 66.29B
Pfizer Inc. 63.70B